NHD Global
Metabolic & Weight Loss · Growth-hormone fragment research
Scientific Product Dossier
AOD-9604 is a modified piece of human growth hormone. It was studied mainly as a possible obesity treatment. The idea was that a small fragment might affect fat metabolism without the broader effects of full growth hormone. The largest human test, the OPTIONS program, enrolled 536 people in a randomized trial. According to the FDA's 2024 review, AOD-9604 did not produce statistically significant weight loss compared with placebo at 12 or 24 weeks, and the sponsor stopped developing it for obesity. No full journal report was found, so regulatory records are the main evidence. This material is for laboratory research only.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The 536-participant program did not show statistically significant weight loss versus placebo at the 12- or 24-week endpoints.
FDA reported that the obesity development program was terminated.
Read the primary studyFDA could not locate a complete medical-journal publication containing the study methods and detailed efficacy results.
Regulatory and sponsor records are therefore central to the evidence map.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
U.S. FDA Pharmacy Compounding Advisory Committee. OPTIONS effectiveness and safety review.
View primary recordWilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
View primary recordThird-party publications selected for direct relevance.
U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Concise answers for researchers comparing identity, evidence and catalog variants.
In the 536-person OPTIONS trial described by the FDA, participants on AOD-9604 did not lose significantly more weight than those on placebo at 12 or 24 weeks. This negative result led the sponsor to stop obesity development. The full trial report was not found, so the FDA review and early development records are the main sources.
The key test was the OPTIONS program, a randomized study comparing the fragment with placebo at 12 and 24 weeks. According to the FDA's review, people taking AOD-9604 did not lose significantly more weight than those taking placebo at either time point. The sponsor then ended the obesity program. No complete trial report was located. Today AOD-9604 is studied as an example of how a promising early idea can fail when tested carefully in people.
No. FDA’s review states that weight loss versus placebo at 12 and 24 weeks was too small to reach statistical significance.
Without a complete journal report, methods, missing-data handling and detailed analyses cannot be independently inspected in the usual way.
Family-level identifiers organize the catalog. Confirm the supplied form, identity and release criteria using the applicable product specification and ask which lot records are available.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
AOD-9604 progressed beyond animal work into an obesity-development program. FDA’s 2024 review records that the large OPTIONS study did not show statistically significant weight…
Updated October 1, 2026
AOD-9604 is a modified growth-hormone fragment developed around a lipolysis hypothesis. Preclinical plausibility and early development do not override the larger null obesity trial.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: AOD2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
